Standardization of Thrombaptanib Drug Substance for Residual Organic Solvents


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Только для подписчиков

Аннотация

Results from experiments conducted for the parameter Residual Organic Solvents during the course of developing a draft regulation for the drug substance of the innovative pharmacological agent thrombaptanib are reported. The structure of the compound is given. Its pharmacological action is described. A list of potential residual organic solvents was compiled by analyzing the synthetic scheme and manufacturing technology. A separate part of the work describes in detail a developed GC-MS procedure for determining residual organic solvents. Validation results of the procedure for Specificity, Linearity, Accuracy, Precision, and Reproducibility are presented. The validation protocol for the procedure at the time of the studies followed domestic guides for validation that were written based on existing international documents because there was no existing GPM for validation in the current edition of the SP RF. A test sample of thrombaptanib was analyzed using the developed procedure for Residual Organic Solvents. The developed procedure was included in the Residual Organic Solvents section of the draft regulation.

Об авторах

A. Petukhov

I. M. Sechenov First Moscow State Medical University; Moscow Narcology Research and Practice Center, Moscow City Department of Health

Email: a-l-e-x4@yandex.ru
Россия, Moscow, 119991; Moscow, 103390

E. Petrykina

I. M. Sechenov First Moscow State Medical University

Email: a-l-e-x4@yandex.ru
Россия, Moscow, 119991

O. Tereshkina

I. M. Sechenov First Moscow State Medical University

Email: a-l-e-x4@yandex.ru
Россия, Moscow, 119991

G. Ramenskaya

I. M. Sechenov First Moscow State Medical University

Email: a-l-e-x4@yandex.ru
Россия, Moscow, 119991

O. Antipova

APTO-FARM Company

Автор, ответственный за переписку.
Email: a-l-e-x4@yandex.ru
Россия, Moscow, 115230

A. Turashev

APTO-FARM Company

Email: a-l-e-x4@yandex.ru
Россия, Moscow, 115230

E. Zav’yalova

APTO-FARM Company; Department of Chemistry, M. V. Lomonosov Moscow State University

Email: a-l-e-x4@yandex.ru
Россия, Moscow, 115230; Moscow, 119991

A. Golovin

APTO-FARM Company; Department of Bioengineering and Bioinformatics, M. V. Lomonosov Moscow State University

Email: a-l-e-x4@yandex.ru
Россия, Moscow, 115230; Moscow, 119991

G. Pavlova

APTO-FARM Company; Institute of Gene Biology, Russian Academy of Sciences

Email: a-l-e-x4@yandex.ru
Россия, Moscow, 115230; Moscow, 119334

A. Kopylov

APTO-FARM Company; Department of Chemistry, M. V. Lomonosov Moscow State University

Email: a-l-e-x4@yandex.ru
Россия, Moscow, 115230; Moscow, 119991


© Springer Science+Business Media, LLC, part of Springer Nature, 2018

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах